免疫检查点抑制剂在小细胞肺癌中的临床研究进展

小细胞肺癌（small cell lung cancer,SCLC）是分化较差的高级别肺神经内分泌肿瘤,尽管仅占所有肺癌的14%左右,但生长迅速、较早出现转移,复发后缺少有效的治疗手段,改善SCLC治疗迫在眉睫。近年来,肿瘤免疫治疗展现了良好的前景,尤其程序性死亡受体1（programmed death 1,PD-1）和细胞毒性T淋巴细胞相关抗原4（cytotoxic T-lymphocyte-associated antigen 4,CTLA-4）抑制剂的研究正在改变多种实体瘤的临床实践。SCLC与吸烟密切相关,具有较高的肿瘤突变负荷,是免疫治疗潜在理想的肿瘤类型。本文将总结免疫治疗在SCL...

Full description

Saved in:
Bibliographic Details
Published inZhongguo fei ai za zhi Vol. 20; no. 9; pp. 623 - 628
Main Author 张爽 柳菁菁 程颖
Format Journal Article
LanguageChinese
English
Published 天津市和平区南京路228号300020 吉林省肿瘤医院胸部肿瘤内科,长春,130012 20.09.2017
中国肺癌杂志编辑部
Subjects
Mini-Review
免疫检查点
免疫检查点抑制剂
小细胞肺癌
综述
Small cell lung cancer
小细胞肺癌
Immune checkpoint
Immune checkpoint inhibitor
免疫检查点
免疫检查点抑制剂
Online AccessGet full text

Cover

More Information
Summary:小细胞肺癌（small cell lung cancer,SCLC）是分化较差的高级别肺神经内分泌肿瘤,尽管仅占所有肺癌的14%左右,但生长迅速、较早出现转移,复发后缺少有效的治疗手段,改善SCLC治疗迫在眉睫。近年来,肿瘤免疫治疗展现了良好的前景,尤其程序性死亡受体1（programmed death 1,PD-1）和细胞毒性T淋巴细胞相关抗原4（cytotoxic T-lymphocyte-associated antigen 4,CTLA-4）抑制剂的研究正在改变多种实体瘤的临床实践。SCLC与吸烟密切相关,具有较高的肿瘤突变负荷,是免疫治疗潜在理想的肿瘤类型。本文将总结免疫治疗在SCLC的临床研究进展,探讨SCLC免疫治疗中存在的问题、面临的挑战以及未来的应用前景。
Bibliography:Small cell lung cancer（SCLC） is a poorly differentiated high-grade neuroendocrine tumor, accounts for approximately 14% of all lung cancers. SCLC is characterized by rapid growth, early metastasis without effective treatments after recurrence. It is urgently need to improve the therapy of patients with SCLC. In recent years Tumor immunotherapy has shown promising efficacy, especially in immune checkpoints including inhibitors programmed cell-death protein 1（PD-1） and cytotoxic T-lymphocyte-associated protein 4（CTLA-4）. These immune checkpoint inhibitors of the researches are changing the clinical practice of many kinds of solid tumor. SCLC is a potential ideal type of tumor immunotherapy for tobacco exposure and the highest mutational load. In this report, the authors review the current state of the immunotherapy in SCLC, to discussing the problems, challenge and application development prospect.
Small cell lung cancer; Immune checkpoint; Immune checkpoint inhibitor
12-1395/R
Shuang ZHANG, Jingjing LIU, Ying CHE
ISSN:1009-3419
1999-6187
DOI:10.3779/j.issn.1009-3419.2017.09.06